Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

IGC Pharma, Inc. (IGC) had Revenue of $0.33M for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$0.33M
Net Income	$-1.20M
Cost of Goods Sold	$0.18M
Gross Profit	$0.15M
Operating Expenses	$1.74M
Operating Income	$-1.41M
Non-Operating Income/Expense	$0.21M
Pre-Tax Income	$-1.20M
Normalized Pre-Tax Income	$-1.20M
Income after Taxes	$-1.20M
Income from Continuous Operations	$-1.20M
Consolidated Net Income/Loss	$-1.20M
Normalized Income after Taxes	$-1.20M
EBIT	$-1.41M
EBITDA	$-1.26M
Weighted-Average Shares Outstanding (Basic)	76.52M
Weighted-Average Shares Outstanding (Diluted)	76.52M
Earnings per Share (EPS) (Basic)	$-0.02
Earnings per Share (EPS) (Diluted)	$-0.02
Balance Sheet Financials
Current Assets	$2.90M
Property, Plant, and Equipment	$3.22M
Long-Term Assets	$5.85M
Total Assets	$8.75M
Current Liabilities	$2.26M
Long-Term Debt	$0.13M
Long-Term Liabilities	$0.16M
Total Liabilities	$2.42M
Common Equity	$6.33M
Tangible Shareholders Equity	$4.48M
Shareholders Equity	$6.33M
Common Shares Outstanding	80.88M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-4.79M
Cash Flow from Investing Activities	$-0.44M
Cash Flow from Financial Activities	$4.45M
Beginning Cash	$1.20M
End Cash	$0.41M
Increase/Decrease in Cash	$-0.79M
Stock-Based Compensation	$1.64M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.28
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.02
Debt to Equity Ratio	0.02
Gross Margin	46.67%
Operating Margin	-427.88%
EBIT Margin	-427.88%
EBITDA Margin	--
Pre-Tax Profit Margin	-362.73%
Profit Margin	-362.73%
Free Cash Flow	$-4.87M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.04
Inventory Turnover	0.13
Receiveable Turnover	9.71
Days Sales in Receivables	9.27
Return on Equity	-18.91%
Return on Tangible Equity	-26.73%
Return on Assets	-13.68%
Return on Investments	-18.52%
Book Value Per Share	$0.08
Free Cash Flow per Share	$-0.06
Operating Cash Flow per Share	$-0.06

Data from Zacks Investment Research, Inc.